Working with TipRanks
Follow Us
Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Calendars
Economic Indicators
Calculators
Education
About Us
Working with TipRanks
Follow Us
PDS Biotechnology Corporation (PDSB)
NASDAQ:PDSB
Holding PDSB?
Track your performance easily
PDSB Stock Chart & Stats
Day’s Range$0 - $0
52-Week Range$2.53 - $6.85
Previous Close$3.37
Volume452.53K
Average Volume (3M)315.80K
Market Cap
$124.08M
Enterprise Value$90.76M
Total Cash (Recent Filing)$57.70M
Total Debt (Recent Filing)$24.38M
Price to Earnings (P/E)―
Beta1.75
Next Earnings
Nov 12, 2024EPS Estimate
-$0.28Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-1.23
Shares Outstanding36,819,810
10 Day Avg. Volume213,914
30 Day Avg. Volume315,802
Standard Deviation0.34
R-Squared0.08
Alpha0.02
Financial Highlights & Ratios
Price to Book (P/B)4.01
Price to Sales (P/S)N/A
Price to Cash Flow (P/CF)-3.50
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit10.00T>
Enterprise Value/Ebitda-2.53
Forecast
1Y Price Target
$13.50Price Target Upside300.59% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering4
PDS Biotechnology News
PremiumCompany Announcements
PDS Biotech Advances with Promising Versamune® HPV Trial Results
PremiumCompany Announcements
PDS Biotechnology Enhances and Modulates Stock Sales Agreement
Bulls Say, Bears Say
Bulls Say
Clinical StrategyPDS Biotechnology will shift focus from doublet development to the triplet, which is expected to materially increase the probability of success due to previously observed additive efficacy benefits.
Efficacy DataThe decision to focus on the triplet is data-driven and backed by a recent study demonstrating durable survival and impressive confirmed response rates.
Survival DataThe majority of patients have now survived beyond 14 months, exceeding the median overall survival of standard care Keytruda monotherapy.
Bears Say
Market EntryThe 1+ year potential delay to timing of market entry drives a price target trim from $14 to $11.
PrognosisHPV-pos status and low PDL1 expression remain key variables associated with poor prognosis against current SoC.
Program DelayThe shift to the new treatment combination has delayed the start of a registration-enabling program, affecting the stock's performance.
---
Ownership Overview
153.94%
Insiders
559.08% Mutual Funds
271.29% Other Institutional Investors
8588.72% Public Companies and
Individual Investors
Risk Analysis
Main Risk Category
Finance & CorporateFinancial and accounting risks. Risks related to the execution of corporate activity and strategy
Website Traffic
Sorry, No Data AvailableThere is no website visitor data available for this stock.
---
PDSB FAQ
What was PDS Biotechnology Corporation’s price range in the past 12 months?
PDS Biotechnology Corporation lowest stock price was $2.53 and its highest was $6.85 in the past 12 months.
What is PDS Biotechnology Corporation’s market cap?
Currently, no data Available
When is PDS Biotechnology Corporation’s upcoming earnings report date?
PDS Biotechnology Corporation’s upcoming earnings report date is Nov 12, 2024 which is in 43 days.
How were PDS Biotechnology Corporation’s earnings last quarter?
PDS Biotechnology Corporation released its earnings results on Aug 13, 2024. The company reported -$0.23 earnings per share for the quarter, beating the consensus estimate of -$0.327 by $0.097.
Is PDS Biotechnology Corporation overvalued?
According to Wall Street analysts PDS Biotechnology Corporation’s price is currently Undervalued.
Does PDS Biotechnology Corporation pay dividends?
PDS Biotechnology Corporation does not currently pay dividends.
What is PDS Biotechnology Corporation’s EPS estimate?
PDS Biotechnology Corporation’s EPS estimate is -$0.28.
How many shares outstanding does PDS Biotechnology Corporation have?
PDS Biotechnology Corporation has 36,819,810 shares outstanding.
What happened to PDS Biotechnology Corporation’s price movement after its last earnings report?
PDS Biotechnology Corporation reported an EPS of -$0.23 in its last earnings report, beating expectations of -$0.327. Following the earnings report the stock price went same 0%.
Which hedge fund is a major shareholder of PDS Biotechnology Corporation?
Among the largest hedge funds holding PDS Biotechnology Corporation’s share is New Leaf Venture Partners, L.L.C.. It holds PDS Biotechnology Corporation’s shares valued at N/A.
---
PDS Biotechnology Stock Smart Score
Unlock Smart Score
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$13.50 (300.59% Upside)
$13.50 (300.59% Upside)
Blogger Sentiment
Bullish
PDSB Sentiment 100%
Sector Average 70%
Sector Average 70%
Hedge Fund Trend
Decreased
By 117.2K Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Positive
Last 7 Days ▲ 0.6%
Last 30 Days ▲ 5.2%
Last 30 Days ▲ 5.2%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-33.92%
12-Months-Change
Fundamentals
Return on Equity
-128.40%
Trailing 12-Months
Asset Growth
-5.11%
Trailing 12-Months
Company Description
PDS Biotechnology Corporation
PDS Biotechnology Corp. engages in the development of clinical-stage immunotherapies to treat various early-stage and late-stage cancers, including head and neck cancer, prostate cancer, breast cancer, cervical cancer, anal cancer, and other cancers. Its products PDS0101, is an off the shelf immunotherapeutic that is administered by subcutaneous injection. The company was founded on March 15, 2019 and is headquartered in Berkeley Heights, NJ.
---
PDSB Earnings Call
Q4 2024
0:00 / 0:00
---
PDSB Stock 12 Month Forecast
Average Price Target
$13.50
▲(300.59% Upside)
Technical Analysis
Best Analysts Covering PDSB
1 Year
1 Year Success Rate
3/12 ratings generated profit
1 Year Average Return
-23.22%
reiterated a buy rating 13 days ago
Copying Joseph Pantginis's trades and holding each position for 1 Year would result in 25.00% of your transactions generating a profit, with an average return of -23.22% per trade.
---